As seen in Forbes.com—Subscribe to the Daily Booster

header image

Upcoming Events

View All Events & Conferences

Our Team

Bob joined the Trout Group in September 2016 and focuses on the Sino-US cross-border banking and strategic consulting service (mainly licensing) and investor relations.  Prior to joining Trout, he was managing director, senior biotech analyst at WallachBeth Capital.  Before that, he was the CFO of Aoxing Pharmaceuticals, a NYSE MKT listed Chinese specialty pharmaceutical company.  He has also served as Principal in crossover life science private equity firm Merlin Nexus and senior equity analysts at assets management firms Bennett Lawrence and Merlin Biomed Group. 

Bob received his PhD and MBA from Penn State University and did postdoctoral training at University of Pennsylvania.  He has published eight articles in peer-reviewed scientific journals.  He also won the prestigious Ray Wu scholarship for outstanding Chinese Student to study abroad. Bob holds Series 7, 63, 79, 86, and 87 securities licenses.

« Back